|Articles|October 2, 2015
- BioPharm International-10-15-2015
- Volume 2015 eBook
- Issue 2
Are Biopharma Patents Poised on the Post-Grant Chopping Block?
Author(s)Scott E. Kamholz
This article examines trends in biopharma post-grant patent review and projects what the future holds in store.
Advertisement
BioPharm International
eBooks Volume 28, Issue 14
Post-grant review of patents at the Patent Trial and Appeal Board (PTAB) has taken the intellectual property (IP) world by storm. Post-grant reviews allow anyone to challenge the validity of a patent far more quickly and cheaply than has ever before been possible. They have replaced the huge financial drain and business risk of traditional patent litigation with a rapid adjudication system that delivers certainty for a price comparable to a patent license fee. Read this article and other articles in
BioPharm International
's 2015
eBook.
Articles in this issue
about 10 years ago
Fluctuating Capacity and Demand Conditions in Biomanufacturingabout 10 years ago
Cleaning Validation for Biologicsabout 10 years ago
Automation of Single-Use Systemsabout 10 years ago
Raising the Bar for Biopharma TrainingNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
